Abstract The VARC (Valve Academic Research Consortium) for transcatheter aortic valve
replacement set the standard for selecting appropriate clinical endpoints reflecting safety …

The von Willebrand factor (vWF) is a plasma protein that mediates platelet adhesion and
leukocyte recruitment to vascular injury sites and carries coagulation factor VIII, a building …

Background: No randomized study powered to compare balloon expandable (BE) with self
expanding (SE) transcatheter heart valves (THVs) on individual end points after …

Background: The main risk factor for bleeding in patients with continuous-flow mechanical
circulatory support (CF-MCS) is the acquired von Willebrand factor (VWF) defect related to …

Transcatheter aortic valve replacement (TAVR) has gained over time a major reduction in
procedural complications. Despite this, clinically relevant bleeding still occurs in a non …

A large amount of evidence supports the widespread use of transcatheter aortic valve
replacement (TAVR) among patients who are at low to intermediate risk for surgery …

Calcific aortic stenosis is a progressive disease that has become more prevalent in recent
decades. Despite advances in research to uncover underlying biomechanisms, and …

BACKGROUND: Thrombocytopenia has been consistently described in patients with
extracorporeal membrane oxygenation (ECMO) and associated with poor outcome …

Abstract Background: Periprocedural and late (> 30 days) bleedings represent major
complications after transcatheter aortic valve replacement and have been identified as …

Transcatheter aortic valve implantation (TAVI) has become an alternative to surgical aortic
valve replacement for patients with symptomatic severe aortic stenosis in elderly and …